Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Cross-Over Placebo-Controlled and Active-Controlled Trial To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia

NCT05893862 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT05893862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05893862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Cross-Over Placebo-Controlled and Active-Controlled Trial To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 1
Overall status
Completed
Start date
June 26, 2023
Completion date
February 22, 2024
Enrollment
107 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia